NEW YORK (GenomeWeb News) – BG Medicine said today that the Nasdaq Listing Qualifications Panel has granted its request to transfer its listing from the Nasdaq Global Market to the Nasdaq Capital Market.

BG requested the transfer, which is effective at open of business today, after failing to meet the $50 million market value of listed securities requirement for listing on the Global Market. The Capital Market requires a company maintain $35 million market value or $2.5 million in stockholders equity.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.

Oct
10
Sponsored by
PerkinElmer

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.